Raptor drug slows loss of muscle control in Huntington study


Raptor Pharmaceutical's (RPTP) RP103 treatment for Huntington's disease (HD) achieved the main goal of a Phase 2/3 trial of 96 patients by slowing the loss of muscle control compared with a placebo.

The results are from the first 18 months of the three-year study. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs